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ABSTRACT  
Objective: Mucus therapy is one of the therapies for gastric ulcer management aside from proton pump inhibitor (PPI) and H2-blocker medication. 
Bioactive fraction DLBS2411 which comes from Cinnamomum burmannii has been identified as a gastric acid anti-secretory agent by inhibiting the 
activity of hydrogen-potassium adenosine triphosphate (H+/K+ATPase). The study was aimed to evaluate the effect of DLBS2411 as a 
neuroprotective agent in gastric and colon by investigating its regulation on mucus related pathway. 
Methods: Total RNA was extracted from gastric and colon cells followed by quantitative real-time polymerase chain reaction (qPCR) analysis for 
mucus synthesis and mucosal blood flow gene expression. Protein expression of prostaglandin E2 (PGE2) and phosphorylation of IĸB kinase subunit 
alpha (IKKα) was analyzed with enzyme-linked immunosorbent assay (ELISA) kit and western blot. Measurement of nitric oxide (NO), which is 
related to mucosal blood flow, was also analyzed. 
Results: Treatment of DLBS2411 elevated phosphorylation of IKKα and activated nuclear factor-КB (NF-κB) which in turn stimulated mucus 
synthesis and mucosal blood flow. High level of NF-κB increased mucus synthesis pathway by promoting cyclooxygenase-2 (COX-2) and PGE2 
expression, which increased the MUC5AC gene. Activation of NF-κB also increased production of NO, which stimulated mucosal blood flow.  
Conclusion: DLBS2411 is a promising candidate for gastric and colon mucus protection by increasing mucus synthesis and stimulating mucosal 
blood flow.  
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INTRODUCTION 
Epithelial surface of the gastrointestinal tract is covered with the 
mucosal layer. This mucosal layer can be injured by endogenous and 
exogenous substances. These include hydrochloric acid, pepsin, 
Helicobacter pylori, alcohol, and non-steroidal anti-inflammatory 
drugs (NSAIDs) [1]. Excessive exposure to these substances can lead 
to multiple complications such as gastritis and gastric ulcers.  
One of the main pharmacotherapeutic options for these conditions is 
proton pump inhibitor (PPI) or H2 receptor blocker medications 
which help decreases hyperacidity in the stomach [2]. Several 
experiments suggest that most factors that trigger hyperacidity are 
mediated through reactive oxygen species (ROS). ROS is defined as a 
chemically reactive molecule that contains one or more free electron 
in their outer orbital. Aside from causing hyperacidity, ROS also 
causes oxidative damage in the gastric and colon mucosa which 
leads to peptic ulcer. Mucosal layer damage might be caused by a 
low level of endogenous antioxidant or impairment of antioxidative 
enzyme activity of the cells [3, 4].  
Our laboratory has investigated numerous pharmacological effects 
of a natural product for chronic internal diseases [5-8]. Previously, 
bioactive fraction DLBS2411 was reported to decrease the level of 
H+/K+ATPase messenger RNA expression in human embryonic 
kidney and rat gastric parietal cells. DLBS2411 also inhibited gastric 
H+/K+ATPase activity at various pH levels. Furthermore, DLBS2411 
showed free radical scavenging activity and reducing power ability. 
This indicates that DLBS2411 has the potential to be an 
antioxidative agent that can be used to alleviate gastric ulcer 
problems [2].  
Mechanism of gastric mucosa protection is complex. Several factors 
that contribute to this mechanism are mucus secretion, bicarbonate 
secretion, and mucosal blood flow. In vitro studies have reported 
that prostaglandin E2 (PGE2) and nitric oxide (NO) stimulates mucus 
secretion [9, 10]. In regards to these previous findings, the effect of 
DLBS2411 on mucus secretion was further evaluated in this study. 
MATERIALS AND METHODS 
Preparation of bioactive fraction of DLBS2411 
Preparation of bioactive fraction DLBS2411 was done according to 
Tjandrawinata, et al. (2013) [2]. The bark of Cinnamomum 
burmannii (C. burmannii) was purchased from West Sumatra, 
Indonesia. This plant has been identified by the Herbarium 
Bogoriense, Research Center of Biology, Indonesian Institute of 
Sciences with certificate 1261/IPH. 1.02/If.8/XII/2009. The 
extraction process of C. burmannii started with maceration of the 
bark in different solvents. Maceration was done in hot water at 
temperatures around 60 °C–90 °C for 1–2 h. Miscella was collected 
during the filtration process and evaporated by vacuum using a 
rotary evaporator (EandE, Warendorf, Germany) at a temperature 
around 60 °C–80 °C to obtain its concentrate. The concentrate was 
further processed through liquid-liquid extraction (LLE) using 
dichloromethane at a ratio of 1:2 (v/v) to remove any organic 
components. Subsequently, the water phase was collected and then 
evaporated using a rotary evaporator (EandE, Warendorf, Germany) 
at temperature around 50 °C–120 °C to obtain the dry extract. This 
dry extract is referred to as bioactive fraction DLBS2411 which is 
used in this study.  
Maintenance of AGS and Caco-2 cell culture 
AGS (ATCC® CRL-1739) and Caco-2 (ATCC® HTB-37TM) cell lines 
were purchased from American Type Culture Collection (Manassas, 
VA, United States). The AGS cell was propagated in F-12 medium 
containing 10% fetal bovine serum and 1% penicillin/streptomycin 
(Thermo Fisher Scientific, Waltham, Massachusetts, United States); 
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while Caco-2 cell was propagated in minimum essential medium 
with the same composition of serum and antibiotic. For in vitro 
molecular assay, the cells were plated in 6-well plates (BD Falcon, 
New Jersey, United States). All cells were cultured in the same growth 
medium containing 1% penicillin/streptomycin without fetal bovine 
serum and incubated at 37 °C, 5% CO2 for 4 h prior to treatment. The 
cells were treated with DLBS2411 in concentrations of 10 µg/ml and 
25 µg/ml and incubated in a CO2 incubator (New Brunswick Scientific, 
New Jersey, United States) for 24 h at 37 °C, 5% CO2. 
Effect of DLBS2411 on MUC5AC, nuclear factor-κB (NF-κB), 
cyclooxygenase-2 (COX-2) and 15-hydroxyprostaglandin 
dehydrogenase (15-PGDH) gene expression 
Total RNA was extracted using TRIzol® reagent (Thermo Fisher 
Scientific, Waltham, Massachusetts, United States) according to the 
manufacturer’s protocol. The RNA concentration was quantified using 
NanoDrop 2000c spectrophotometer (Thermo Fisher Scientific, 
Waltham, Massachusetts, United States). The expression of several target 
genes were determined using a quantitative real-time polymerase chain 
reaction (qPCR) assay in 25 μl reaction that consisted of 12.5 µl iQTM 
SYBR Green Supermix (Bio-Rad Laboratories, Hercules, CA, USA), 1 μM 
of each targeted primer, and 0.1 µM of each internal control primer 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The quantitative 
real-time PCR was performed using a Mini Opticon MJ MiniTM (Bio-Rad 
Laboratories, Hercules, CA, USA) in optimum conditions for each primer. 
The primers used in this study were (F, forward; R, reverse): MUC5AC 
(F: AGTGGTTCGACGTGGACTTC; R: CTGTCAACCCCTCTGACCAC); NF-κB 
(F: GGGGCATCAAACCTGAAGATTTCT; R: TCCGGAACACAATGGCATA-
CTGT); COX-2 (F: CCGCTCCGGACTAGATGATA; R: GACT CCTTTCT-
CCGCAACAG); 15-PGDH (F: TGCTTCAAAGCATGGCATAG; R: AATCAATG 
GTGGGTCCAAAA). 
Protein preparation from AGS and Caco-2 cells 
AGS and Caco-2 cells were washed in ice-cold PBS and were 
extracted using RIPA buffer containing 50 mM Tris (pH 6.8), 0.5% 
(w/vol) sodium dodecyl sulfate, 150 mM sodium chloride, 1% NP-
40, 2 mM ethylenediaminetetraacetic acid (EDTA) and 1x protease 
inhibitor. Supernatant of the cells were collected by centrifugation at 
1,400 rpm for 15 min at 4˚C using Hettich Mikro 200 centrifuge 
(Hettich, Massachusetts, USA) and stored at-20 ˚C.  
In vitro PGE2 and phosphorylation of IĸB kinase subunit alpha 
(IKKα) Inhibitor assay 
PGE2 and phosphorylation of IKKα were analyzed using an enzyme-
linked immunosorbent assay (ELISA) kit (PGE2, GE Life Sciences, 
United Kingdom) and (IKKα, Cell Signaling Technologies, 
Massachusetts, United States) according to the manufacturer’s 
protocol as described previously [11, 12].  
Western Blot of IKKα/β and pIKKα/β  
Protein concentration was quantified using Lowry method [13]. 
Total cell extracts were electrophorized by the sodium dodecyl 
sulfate-polyacrylamide gel. Proteins were electrotransferred onto 
polyvinylidene difluoride membranes in a semi-dry blotting 
apparatus Transblot Turbo (Bio-Rad Laboratories, California, USA). 
Blots were blocked with 5% (w/vol) dried skim milk in TBS-t for 2 h 
at room temperature and then incubated for 16 h at 4 °C with a 
specific monoclonal mouse anti-human β-actin (diluted 1/1000), 
polyclonal rabbit anti-human IKKα/β and p-IKKα/β (diluted 1/500) 
(Santa Cruz, Texas, United States).  
Blots were then incubated with a horseradish peroxidase-
conjugated anti-mouse and anti-rabbit secondary antibody (diluted 
1/1,000) for 2 h at 25 °C. Immunodetection was performed with 
enhanced chemiluminescence using Chemidoc XRS (Bio-Rad 
Laboratories, California, USA).  
NO production from AGS and caco-2 cells 
AGS and Caco-2 cells were treated with 10-25 μg/ml of DLBS2411 and 
20 µg/ml of sucralfate. After 24 h of treatment, the supernatant of the 
cell was aspirated and put into a 96-well plate. Production of NO was 
measured using the Griess reagent (Sigma-Aldrich, Saint Louis, USA) 
with equal volume to supernatant as described previously [14]. The 
reagent was allowed to stand for 15 min at room temperature in dark 
condition. The absorbance was measured at 520 nm wavelength.  
Statistical analysis of result 
The statistical differences between treatment and control samples 
were determined using Student’s t-test using the Stat-View software 
package (Abacus Concepts, Piscataway, NJ, USA). Values are 
expressed as mean±standard deviation for two independent 
experiments. 
RESULTS  
DLBS2411 increases expression of mucin  
Mucus consists of mucin which provides an important protective 
barrier against acid and pepsin. One of the methods of treating 
gastric and colonic ulcer is by increasing its mucus production. 
Mucus gel is secreted by surface epithelial cells and is formed by a 
large amount of water (about 95%) and various kinds of mucin 
glycoproteins (i.e. MUC2, MUC5AC, MUC5B and MUC6). Our study 
revealed that DLBS2411 significantly stimulated MUC5AC (human 
mucin gene) in transcription level, both in AGS and Caco-2 cells 
[fig. 1A, 1B]. DLBS2411 with a dose of 25 μg/ml was shown to 




Fig. 1: Expression of MUC5AC gene following treatment of (A) 
AGS cell and (B) Caco-2 cells with sucralfate or DLBS2411 for 24 
h. Values are expressed as the means±standard deviation of 
two independent experiments. Asterisk (*) indicates significant 
changes as compared with the control group. Note: *P<0.05 
 
Stimulation of DLBS2411 on PGE2 production in vitro 
Prostaglandin, particularly PGE2, has an important role in 
modulating mucosal integrity. PGE2 has been recognized as an agent 
that can induce the synthesis and secretion of mucus to prevent any 
damage in the gastric mucosa surface. The effect of DLBS2411 on 
PGE2 production was investigated by ELISA. The result showed that 
DLBS2411 stimulated the production of PGE2 in AGS cells (table 1). 
DLBS2411 was shown to be more effective on Caco-2 cells compared 
to AGS cells (table 2). Specifically at dose 25 µg/ml, DLBS2411 was 
more effective in comparison with the control. 
 
Tjandrawinata et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 8, 202-207 
204 
Table 1: PGE2 in AGS cells after 24 h treatment with sucralfate and DLBS2411. 
Sample PGE2 [pg/ml] SD P value 
Control 109.84 2.12 0.000 
DLBS2411 10 μg/ml 118.32 6.80 0.059 
DLBS2411 25 μg/ml 116.11 2.11 0.076 
Sucralfate 20 μg/ml 121.08 2.39 0.055 
Values are expressed as mean±standard deviation of three independent experiments. Asterisk (*) indicates significant changes as compared with 
the control group. Notes: *P<0.05 
 
Table 2: PGE2 in Caco-2 cells after 24 h treatment with sucralfate and DLBS2411. 
Sample PGE2 [pg/ml] SD P value 
Control 33.66 1.3 0.000 
DLBS2411 10 μg/ml 38.10 0.4 0.0446* 
DLBS2411 25 μg/ml 51.76 4.0 0.0260* 
Sucralfate 20 μg/ml 82.17 4.3 0.0099* 
Values are expressed as mean±standard deviation of two independent experiments. Asterisk (*) indicates significant changes as compared with the 
control group. Notes: *P<0.05 
 
DLBS2411 regulates COX-2 and 15-PGDH through NF-κB 
pathway  
In order to investigate the MUC5AC upregulation pathways, the 
effect of DLBS2411 on COX-2 and NF-κB gene was studied. Many 
studies revealed that NF-κB-based transcriptional mechanism is 
involved in MUC5AC regulation. The ultimate step leading to 
MUC5AC gene upregulation is the activation of several transcription 
factors including NF-κB. NF-κB is a crucial regulator of many cellular 
processes, including immune response, inflammation and apoptosis. 
DLBS2411 was administered to AGS and Caco-2 cells at a 
concentration of 10 μg/ml and 25 μg/ml.  
After being treated for 24 h, RNA was isolated and used for real-time 
PCR analysis. The result revealed that NF-κB expression was 
increased along with the increase of DLBS2411 concentration, both 
in AGS and Caco-2 cells (fig. 2A, 2B). The activation of NF-κB 
subsequently is the cause of increased MUC5A gene expression. 
  
 
Fig. 2: (A-D) Effect of DLBS2411 on NF-κB and COX-2 gene expression. (A) Expression of NF-κB gene in AGS and (B) in Caco-2 cells with 
sucralfate or DLBS2411 treatment for 24 h. Expression of COX-2 gene in (C) AGS cells and (D) in Caco-2 cells with sucralfate or DLBS2411 
treatment for 24 h. Values are expressed as mean±standard deviation of two independent experiments. Asterisk (*) indicates significant 
changes as compared with the control group. Note: *P<0.05 
 
Following the discovery of two isoforms of COX, COX-2 is the enzyme 
that triggers pain. It is an inducible pro-inflammatory enzyme which 
is essential in inflammatory cascades where arachidonic acid is 
involved as its substrate and is positively regulated by NF-κB 
activation [15]. Selective COX-2 inhibitors were clinically developed 
as novel anti-inflammatory drugs characterized by increased 
viability of the gastric cell.  
NF-κB acts as a transcription factor for the COX-2 gene. Therefore a 
high level of NF-κB gene expression indicated that COX-2 gene will 
be expressed at a high level. In the present study, COX-2 gene 
expression was increased after treatment of DLBS2411 (fig. 2C, 2D). 
Therefore, it can be concluded that DLBS2411 stimulates PGE2 
production through the COX-2 pathway. Aside from COX-2 gene 
expression, the observation was continued in other pathways that 
Tjandrawinata et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 8, 202-207 
205 
might be affected by DLBS2411. Hence, 15-PGDH gene expression 
which is responsible for PGE2 catabolism in AGS cells was observed.  
 
Fig. 3: Expression of the 15-PGDH gene in AGS cells treated with 
sucralfate or DLBS2411 for 24 h.  
Values are expressed as the means±standard deviation of two 
independent experiments. An asterisk (*) indicates significant changes 
as compared with the control group. Note: *P<0.05 
The result showed that the expression decreased at a dose of 25 
μg/ml (fig. 3). Caco-2 cells do not express the 15-PGDH gene. 
Therefore analysis was only done on AGS cell. The observation was 
conducted using the same experimental procedure as above. 
DLBS2411 induces phosphorylation of IKKα  
In order to affirm the activity of DLBS2411 as NF-κB upregulation, 
measurement of IKKα phosphorylation was conducted. The 
phosphorylation was evaluated using ELISA and western blot 
assays. It was demonstrated that phosphorylation of IKKα increased 
with DLBS2411 treatment (fig. 4A, 4B). The phosphorylation of IKKα 
was also displayed in western blot technique in Caco-2 cells (fig. 4C). 
DLBS2411 increases mucosal blood flow through NO production 
Recent research has highlighted the fact that, other than 
prostaglandin, gastric mucosal protection can be accomplished 
through other mediators, with particular regard to the gaseous 
mediators NO. NO is formed enzymatically from its precursor L-
arginine. It stimulates mucosal blood flow via cyclic 3`, 5`-
monophospate (cGMP) dependent pathway. Production of cGMP is 
stimulated by activation of guanylate cyclase. Guanylate cyclase is 
activated by NO diffusion to the vascular smooth muscle cells. 
Production of NO after treatment with DLBS2411 was observed and 
compared to those affected by sucralfate in AGS and Caco-2 cells (fig. 
5A, 5B). The production of NO exhibited a similar pattern in both 
cells. At a dose of 10 µg/ml, DLBS2411 was able to upregulate NO 
compared to sucralfate. As shown in fig. 5A and 5B, a higher dose of 




Fig. 4: (A-C) Phosphorylation of IKKα protein with the treatment of sucralfate or DLBS2411 added for 24 h.  
Phosphorylation of IKKα in (A) AGS cells and (B) Caco-2 cells were analyzed by ELISA. Values are expressed as mean±standard deviation of two independent 




Fig. 5: DLBS2411 elevated NO production in (A) AGS cells and (B) Caco-2 cells.  
Values are expressed as mean±standard deviation of two independent experiments. Asterisk (*) indicates significant changes as compared with the 
control group. Note: *P<0.05 
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DISCUSSION 
The development of a plant-based drug for treatment of chronic 
diseases, including gastric ulcer treatment, has become more 
popular in recent years. The previous study by Alqasoumi (2012) 
exhibits how the treatment of Cinnamomum zeylanicum extract in 
rats had the capacity to stimulate mucus secretion, making it 
potential to be developed as an antiulcer treatment [16]. Bioactive 
fraction DLBS2411, which is derived from C. burmannii, has been 
proven to confer its effect as gastric acid antisecretory agent [2]. 
Although the effect of DLBS2411 on the expression of H+/K+ATPase 
has previously been evaluated [2], there is still no study on the effect 
of DLBS2411 on mucus synthesis.  
Gastric mucosal layer acts as a barrier that restricts the exposure of 
gastric cells to various injurious agents of both exogenous and 
endogenous origin. Therefore, stimulation of mucus production in 
gaster tissue is one of the central factors in ulcer healing by protecting 
the damaged tissue against aggressors such as harmful drugs and 
oxidants. In fact, secretion of mucus is an important contributor in 
gastric epithelial tissue recovery after acute injury through the 
formation of a mucoid cover. In this study, DLBS2411 was tested to 
verify its role in protecting the mucus layer in gaster and colon.  
Mucus is comprised of glycoproteins, water, and mucin, which is 
regarded as the major structural protein of the mucus. One mucin 
protein, MUC5AC, is located in the pit cells of gastric pit extending to 
part of the surface epithelium [17, 18]. MUC5AC is coded for MUC5AC 
protein that is responsible as secretory mucin. In this study, AGS and 
Caco-2 cells were used to study MUC5AC gene expression. AGS is a 
part of the gastric adenocarcinoma cells that expressed MUC5AC gene, 
while Caco-2 has the highest expression of MUC5AC gene compared to 
other colon cancer cells [19]. DLBS2411 was shown to enhance 
MUC5AC gene expression in AGS and Caco-2 cells.  
One of the stimulators that induce mucus production is PGE2. PGE2 is a 
major component of the protective factors that maintain the 
gastrointestinal mucosal integrity and mucosal microcirculation. It 
could reduce damage caused by necrotizing agents (such as alcohol, 
aspirin and bile salts) in the gastric mucosal barriers and inhibit 
gastric acid secretion [20]. PGE2 analog was reported to increase the 
thickness of mucus gel in rat gastric mucosa [21, 22]. In rat and 
human, prostaglandin stimulates synthesis of mucus in gastric, 
elevates the mucus gel layer and maintains the pH gradient as well as 
increasing mucus viscosity [23]. Therefore, prostaglandin was also 
examined in order to confirm the effect of prostaglandin production to 
mucus synthesis. The present study shows that DLBS2411 was able to 
elevate PGE2 production in Caco-2 cells. However, elevation in AGS cell 
was not significant (table 1, 2). This result is in accordance with the 
study of Shindo et al. (2006) which stated that prostaglandin exerts a 
stimulatory effect on mucus production [23].  
Expression of MUC5AC gene is regulated by NF-κB gene expression 
as its transcription factor. Similar to sucralfate, DLBS2411 was 
shown to up-regulate the expression of NF-κB gene (fig. 2A, 2B). 
Sucralfate has been known to have potassium sucrose octa sulfate 
(SOS) as the major soluble functional element. SOS is known for its 
anti-apoptotic mechanism and works through activation of NF-κB 
pathway [24]. NF-kB signaling pathway is an important innate 
defense mechanism in human [25], yet it is also responsible for the 
inflammatory reaction in the body. Some harmful stimuli can cause 
inflammatory responses by activation of NF-κB pathway. However, 
some conditions might disrupt inflammatory responses and 
repressed mucin production [26, 27].  
Since NF-κB gene regulates COX-2 gene expression, the COX-2 level 
was also examined in this study. COX-2 is known to stimulate 
prostaglandin production which mediated the inflammation process 
[28]. However, the COX-2 expression is also related to gastric 
protection. Several studies have shown that COX-2 inhibitor can 
elicit gastric damage [20, 29]. The up-regulation of COX-2 expression 
in intestinal epithelial cells after treatment of sucralfate was evident 
in the study by Shindo, et al. (2006) (fig. 2C, 2D) [24]. 
Prostaglandin catabolism is catalyzed by NAD+-dependent 15-PGDH 
[28]. Expression of 15-PGDH was identified in an SGC7901 cell with 
COX-2/siRNA treatment [22]. DLBS2411 was shown to down-
regulate the 15-PGDH gene expression at a dose of 25μg/ml in the 
gastric cell (fig. 3). Similar mechanism was also demonstrated by 
rebamipide as a mucoprotective drug. The drug was able to 
downregulate 15-PGDH expression, yet increase COX-2 and PGE2 
synthesis [30].  
In resting cells, NF-κB is bound to the cytoplasmic NF-κB inhibitors 
(IκBα) in its inactive form. Therefore, NF-κB activation requires 
phosphorylation of IκBα. Stimulation such as up-regulation of 
cytokines results in the activation of specific intracellular signaling 
pathways with subsequent activation of the IKK complex. This 
complex comprises of two catalytic subunits (IKKα and IKKβ) and 
the regulatory subunit (IKKγ), which then phosphorylates IκBα in 
their active form. Phosphorylation leads to ubiquitination and 
degradation of IκBα, thereby releasing NF-κB from the complex 
where it translocates to the nucleus and activates gene that are 
responsible for the gastric mucosal integrity, such as COX-2 [25]. In 
this experiment, it was shown that IKKα was phosphorylated with 
DLBS2411 treatment (fig. 4A-4C), while control cell remained 
unphosphorylated. Another possible mechanism of DLBS2411 was 
also evaluated, for example, the ability of DLBS2411 to protect 
gastric and colon cells through NO elevation [10]. It is shown that 
DLBS2411 up-regulated the production of NO (fig. 5A, 5B), which 
increased gastric blood flow and maintained gastric 
microcirculation. Therefore, it can be inferred that DLBS2411 was 
able to increase the mucosal blood flow through NO production.  
Another study suggests that DLBS2411 has antioxidative activity. 
DLBS2411 was proven to possess free radical scavenging activity 
and reducing power ability [2]. It was also shown that DLBS2411 
was able to reduce the number of petechiae in a dose-dependent 
manner in rats [2]. Antioxidant activity is suggested to have a 
positive correlation with mucus healing property [23, 30].  
In this study, sucralfate as an approved gastro protective drug was 
used as positive control. In several experiments with sucralfate, it is 
shown that sucralfate stimulated prostaglandin and mucus secretion 
and elevated the mucosal blood flow [31, 32]. The result of this 
study proved that DLBS2411 works similarly to sucralfate. Since 
DLBS2411 exhibits similar activity to sucralfate, DLBS2411 can be 
deemed as a promising candidate for gastric ulcer treatment.  
CONCLUSION 
DLBS2411 has gastric and colon protective effect through several 
pathways (fig. 6). DLBS2411 elevates phosphorylation of IKKα and 
activate NF-κB. High level of NF-κB affects several pathways; 
promotes transcription of MUC5AC and COX-2, and increases 
production of NO. High expression of COX-2 has a reverse effect on 
expression of 15-PGDH. The COX-2 gene affects the metabolism of 
PGE2 which will regulate MUC5AC expression. High expression of 
MUC5AC stimulates gastric and colon mucus synthesis. High 
production of NO by NF-κB expression increases mucosal blood 
flow. Therefore, it is evident that DLBS2411 promotes mucus 
healing by stimulating gastric mucus synthesis and secretion.  
 
 
Fig. 6: Proposed mechanism of action of DLBS2411 
Tjandrawinata et al. 
Int J Pharm Pharm Sci, Vol 8, Issue 8, 202-207 
207 
ACKNOWLEDGEMENT 
The authors would like to thank Irfan Darfiansyah for the 
preparation of DLBS2411 and also Prof. Maggy T. Suhartono, Hanna 
C. Rouli and Guntur Berlian for their assistance in editing this 
manuscript. 
CONFLICTS OF INTERESTS 
The authors report no conflicts of interest in this work. 
REFERENCES 
1. Smolka AJ, Backert S. How Helicobacter pylori infection controls 
gastric acid secretion. J Gastroenterol 2012;47:609–18. 
2. Tjandrawinata RR, Nailufar F, Arifin PF. Hydrogen potassium 
adenosine triphosphatase activity inhibition and 
downregulation of its expression by bioactive fraction 
DLBS2411 from Cinnamomum burmannii in gastric parietal 
cells. Int J Gen Med 2013;6:807-15. 
3. Luiz-Ferreira A, Cola M, Barbastefano V, Meira de-faria F, 
Almeida AB, Farias-silva E, et al. Healing, antioxidant and 
cytoprotective properties of Indigofera truxillensis in different 
models of gastric ulcer in rats. Int J Mol Sci 2012;13:14973-91. 
4. Kwiecien S, Brzozowski T, Konturek SJ. Effect of reactive 
oxygen species action on gastric mucosa in various models of 
mucosal injury. J Physiol Pharmacol 2002;53:39-50.  
5. Tandrasasmita OM, Wulan DD, Nailufar F, Sinambela J, 
Tjandrawinata RR. Glucose-lowering effect of DLBS3233 is 
mediated through phosphorylation of tyrosine and 
upregulation of PPARγ and GLUT4 expression. Int J General 
Glucose-Lowering Effect Med 2011;4:345-57. 
6. Tandrasasmita OM, Sutanto AM, Arifin PF, Tjandrawinata RR. 
The anti-inflammatory, antiangiogenic, and apoptosis-inducing 
activity of DLBS1442, a bioactive fraction of Phaleria 
macrocarpa, in a RL95-2 cell line as a molecular model of 
endometriosis. Int J Women’s Health 2015;7:161-9. 
7. Karsono AH, Tandrasasmita OM, Tjandrawinata RR. Molecular 
effects of bioactive fraction of Curcuma mangga (DLBS4847) as 
a downregulation of 5α-reductase activity pathways in 
prostatic epithelial cells. Cancer Manag Res 2014;6:267-78. 
8. Nailufar F, Tandrasasmita OM, Tjandrawinata RR. DLBS3233 
increases glucose uptake by mediating upregulation of PPARγ 
and PPARδ expression. Biomed Prev Nutr 2011;1:71–8. 
9. Phillipson M, Johansson ME, Henriksnäs J, Petersson J, Gendler 
SJ, Sandler S, et al. The gastric mucus layers: constituents and 
regulation of accumulation. Am J Physiol Gastrointest Liver 
Physiol 2008;295:G806-12.  
10. Brown JF, Hanson PJ, Whittle BJ. Nitric oxide donors increase 
mucus gel thickness in rat stomach. J Pharmacol 1992;223:103-4. 
11. Tjandrawinata RR, Dahiya R, Hughes-Fulford M. Induction of 
cyclo-oxygenase-2 mRNA by prostaglandin E2 in human 
prostatic carcinoma cells. Br J Cancer 1997;75:1111-8. 
12. Tjandrawinata RR, Hawell L, Byus CV. Characterization of 
putrescine and cadaverine export in mammalian cells. 
Biochemical Pharmacol 1994:48:2237-49. 
13. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein 
measurement with the folin phenol reagent. J Biol Chem 
1951;93:265-75. 
14. Tjandrawinata RR, Byus CV. Regulation of the efflux of putrescine 
and cadaverine from rapidly growing cultured RAW 264 cells by 
extracellular putrescine. Biochemical J 1995;1:291-9. 
15. Hughes-Fulford M, Tjandrawinata RR, Li CF, Sayyah S. 
Arachidonic acid, an omega-6 fatty acid, induces cytoplasmic 
phospholipase A2 in prostate carcinoma cells. Carcinogenesis 
2005;26:1520-6. 
16. Alqasoumi S. Anti-secretagogue and antiulcer effects of 
'Cinnamon' Cinnamomum zeylanicum in rats. J Pharmacogn 
Phytother 2012;4:53-61. 
17. Ho SB, Takamura K, Anway R, Shekels LL, Toribara NW, Ota H. 
The adherent gastric mucous layer is composed of alternating 
layers of MUC5AC and MUC6 mucin proteins. Dig Dis Sci 
2004;49:1598–606. 
18. Ho SB, Roberton AM, Shekels LL, Lyftogt CT, Niehans GA, 
Toribara NW. Expression cloning of gastric mucin 
complementary DNA and localization of mucin gene 
expression. Gastroenterology 1995;109:735-47. 
19. Bu X, Li N, Tian X, Huang P. Caco-2 and LS174T cell lines 
provide different models for studying mucin expression in 
colon cancer. Tissue Cell 2011;43:201–6. 
20. Halter F, Tarnawski AS, Schmassmann A. Cyclooxygenase 2-
implications on maintenance of gastric mucosal integrity and 
ulcer healing: controversial issues and perspectives. Gut 
2001;49:443-53. 
21. Bickel M. Effect of 16,16-dimethyl prostaglandin E2 on gastric 
mucus gel thickness. Prostaglandins 1981;2:63-5. 
22. Tanigawa T, Watanabe T, Ohkawa F, Nadatani Y, Otani K, 
Machida K, et al. Rebamipide, a mucoprotective drug, inhibits 
NSAIDs-induced gastric mucosal injury: possible involvement 
of the downregulation of 15-hydroxyprostaglandin 
dehydrogenase. J Clin Biochem Nutr 2011;48:149-53. 
23. Choi SM, Shin JH, Kang KK, Ahn B, Yoo M. Gastroprotective 
effects of DA-6034, a new flavonoid derivative in various 
gastric mucosal damage models. Dig Dis Sci 2007;52:3075–80.  
24. Shindo K, Iizuka M, Sasaki K, Konno S, Itou H, Horie Y, et al. 
Sucralfate prevents the delay of wound repair in intestinal 
epithelial cells by hydrogen peroxide through NF-κB pathway. J 
Gastroenterol 2006;41:450–61. 
25. Lawrence T. The nuclear factor NF-ĸB pathway in 
inflammation. Cold Spring Harbor Perspect Biol 
2009;1:a001651. Doi:10.1101/cshperspect.a001651. [Article 
in Press] 
26. Xue Y, Zhang H, Wang H, Hu J, Du M, Zhu M. Host inflammatory 
response inhibits Escherichia coli O157:H7 adhesion to gut 
epithelium through augmentation of mucin expression. Infect 
Immun 2014;82:1921-30. 
27. Slomiany BL, Slomiany A. Cytosolic phospholipase A2 activation 
in Helicobacter pylori lipopolysaccharide-induced interference 
with gastric mucin synthesis. Life 2006;58:217-33. 
28. Backlund MG, Mann JR, Holla VR, Buchanan FG, Tai H, Musiek 
ES, et al. 15-hydroxyprostaglandin dehydrogenase is down-
regulated in colorectal cancer. J Biol Chem 2005;280:3217–23. 
29. Liu Z, Wang X, Lu Y, Han S, Zhang F, Zhai H, et al. Expression of 
15-PGDH is downregulated by COX-2 in gastric cancer. 
Carcinogenesis 2008;29:1219-27. 
30. Lamont JT. Mucus: the front line of intestinal mucosal defense. 
Ann N Y Acad Sci 1992;664:190–201.  
31. Wallace JL. Prostaglandin, NSAIDs and gastric mucosal 
protection: why doesn't the stomach digest itself? Physiol Rev 
2008;88:1547-65. 
32. Hollander D, Tarnawski A. The protective and therapeutic 
mechanisms of sucralfate. Scand J Gastroenterol 1990;25 Suppl 
173:1-5. 
How to cite this article 
• Anggi S Wulandari, Olivia M Tandrasasmita, Raymond R 
Tjandrawinata. Bioactive fraction dlbs2411 from Cinnamomum 
Burmanii, (nees and t. nees) blume as colon and 
gastroprotector by stimulating muc5ac and cyclooxygenase-2 
gene expression. Int J Pharm Pharm Sci 2016;8(8):202-207. 
 
